Related Experiment Videos
Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects
J A Widness1, P Veng-Pedersen, C Peters
1Department of Pediatrics, College of Medicine, University of Iowa, Iowa City 52242, USA.
Insights
Erythropoietin (EPO) pharmacokinetics differ in premature infants compared to adults. Chronic recombinant human EPO (rhEPO) treatment alters infant EPO clearance, suggesting dose adjustments for anemia treatment.
Area of Science:
- Pharmacology
- Neonatology
- Pediatrics
Background:
- Erythropoietin (EPO) is crucial for red blood cell production.
- Premature infants often require EPO for anemia management.
- Understanding EPO pharmacokinetics is vital for effective treatment.
Purpose of the Study:
- To investigate erythropoietin (EPO) pharmacokinetics in premature infants.
- To compare EPO pharmacokinetics between premature infants and adults.
- To assess the impact of chronic recombinant human EPO (rhEPO) treatment on infant pharmacokinetics.
Main Methods:
- Pharmacokinetic studies using intravenous rhEPO at escalating doses (10, 100, 500 IU/kg) in adults and infants.
- Comparison of rhEPO pharmacokinetics in treated versus untreated infant subgroups.
- Analysis of plasma clearance, distribution volume, fractional elimination time (FET), and mean residence time (MRT).
Main Results:
- Very low birth weight infants exhibited greater plasma clearance and distribution volume than adults.
- Both infants and adults showed nonlinear EPO elimination with increasing doses.
- Chronic rhEPO treatment in infants led to increased clearance and reduced FET and MRT.
Conclusions:
- Premature infants have distinct EPO pharmacokinetics compared to adults.
- Chronic rhEPO treatment significantly alters EPO pharmacokinetics in infants.
- Optimizing rhEPO efficacy for infant anemia may necessitate higher, progressively increasing doses.
Abstract:
Erythropoietin (EPO) pharmacokinetic studies were performed in premature infants (birth weight < 1.25 kg) and normal adults. Infants were divided into two subgroups on the basis of whether they received chronic treatment with recombinant human EPO (rhEPO; 500 IU.kg-1.wk-1 for 6 wk) beginning at 2-4 wk of life. Ten adults and seven rhEPO-treated infants underwent intravenous pharmacokinetic studies at escalating rhEPO doses: 10, 100, and 500 IU/kg. To test for pharmacokinetic developmental and treatment effects, an equal number of non-EPO- and EPO-treated infants were studied with 100 IU/kg on the last day of treatment. Compared with adults, very low birth weight infants demonstrated significantly greater plasma clearance and distribution volume and significantly shorter fractional elimination times (FET) and mean residence time (MRT) at all three rhEPO doses. Both infants and adults demonstrated nonlinear EPO elimination, i.e., increasing rhEPO dosing was associated with decreasing plasma clearance and increasing FET and MRT. In the absence of rhEPO treatment there were no pharmacokinetic differences between the two subgroups of infants studied 6 wk apart. In contrast, the rhEPO-treated infant subgroup demonstrated a significant increase in clearance and a decrease in FET and MRT following 6 wk of treatment. Enhancement of rhEPO efficacy in the prevention and treatment of anemia in premature infants may require higher doses administered in a progressively increasing fashion.